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Abstract
At the start of the last decade, we provided evidence that levels of the peptide neurokinin B were highly elevated
in pre-eclampsia. We hypothesized that elevated levels of neurokinin B may be an indicator of pre-eclampsia and
that treatment with certain neurokinin receptor antagonists may be useful in alleviating the symptoms. At the time
of the original hypothesis many questions remained outstanding. These included - Does neurokinin B have any
diagnostic value in the detection and diagnosis of pre-eclampsia? - What is the cause of the elevated levels of
neurokinin B during pre-eclampsia? - What is the physiological significance of neurokinin B in the placenta? This
review discusses the answers to these questions taking into account the subsequent developments of the past ten
years and analyzing the plethora of discoveries that have arisen from those initial observations.
Background
The precise origin of pre-eclampsia remains elusive, but
it is believed to be multifactorial and to include a sce-
nario of required steps [1]. One crucial step is defective
trophoblast invasion, which is thought to lead to
reduced placental perfusion. We have believed, like
many others that a poorly diffused and ischaemic pla-
centa releases an excess of a factor(s) and, it is this fac-
tor(s) that leads to the cascade of events defined as the
clinical syndrome of pre-eclampsia. Roberts [2] pre-
dicted that any candidate molecule(s) would not be
unique but rather a known molecule(s) that is present
in excessive amounts. In addition, any factor is likely to
be placental in origin as it is accepted that it is the pre-
sence of the placenta rather than the fetus, which is
responsible for the development of pre-eclampsia [3]. In
the late 1990s we sought to identify potential secreted
factors from the placenta using mRNA fingerprinting [4]
and the human genomic databases [5] and found nine
matches that showed high similarity to the bovine neu-
rokinin B (NKB) precursor [6]. In all, we identified more
than 2,000 sequences of known genes; expressed
sequence tags and uncharacterized genes. These genes
have also included variants of pregnancy associated
plasma protein-E [7], the apolipoprotein L proteins [8]
and the tachykinin gene-related peptides [9].
From all the candidates NKB, which is a member of
the tachykinin family [10], appeared to be the most pro-
mising as a potential marker and factor to cause pre-
eclampsia. The placenta was found to express unusually
high levels of TAC3 that encodes NKB [11], a gene pre-
viously believed not to be expressed in any peripheral
tissue [12]. This expression was located to the outer
syncytiotrophoblasts in an ideal position for secretion
into the maternal blood [6]. In translational terms sig-
nificant amounts of immunoreactive human NKB were
found in early and term placenta, and maternal plasma,
which had identical chromatographic properties to syn-
thetic NKB [6,13]. Using a commercial radioimmunoas-
say (RIA), NKB plasma concentrations were found to be
low or undetectable from normotensive pregnancies
although a proportion did exhibit a slight rise at term.
Four normotensive pregnancies between weeks 9 and 14
also had concentrations equivalent to the highest at
term. From eight pre-eclamptic women tested in their
third trimester all were found to have considerably
higher levels of NKB [6]. NKB was also found in cord
blood indicating that the secreted peptide could also
enter and affect the feto-placental circulation, however,
i t sr o l ei nt h ef e t u si su n k n o w n[ 6 ] .I nt e r m so fam a r -
ker, placental NKB appeared to have several advantages
over other candidate markers as it appeared not only
unique to pre-eclampsia but also to pregnancy and was
not associated with other known hypertensive disorders
[5]. In addition, evidence from the infusion of high
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be involved in some of the haemodynamic events of
pre-eclampsia [6,11]. Here, NKB was found to cause
substantial pressor activity (believed initiated through
the NKB preferred receptor NK3) and a 37% gain in
uterine weight providing indirect evidence for an
increase in blood supply to the uterus [6]. We, therefore,
proposed that NKB could be a signal sent from the pla-
centa to the mother in order to maximize blood flow to
the feto-placental unit. It is also possible for NKB to
progressively stimulate other NK receptors (NK1 and
NK2) and cause the additional clinical features asso-
ciated with pre-eclampsia such as thrombocytopenia
[14], generalized inflammation [15], oedema [16] and
eclampsia [17]. Nonetheless, at the time we proposed
our original hypothesis many outstanding questions still
remained. These included amongst others - does NKB
have any diagnostic value in the detection and diagnosis
of pre-eclampsia and what is the cause of the elevated
levels of NKB during pre-eclampsia? What is the physio-
logical significance of NKB in the placenta? We shall
review the subsequent developments in each of these
areas in turn.
Does NKB have any diagnostic value?
In the case for a diagnostic marker the measurement of
elevated levels of NKB in pregnancies complicated by
pre-eclampsia has been subsequently confirmed in sev-
eral studies [6,18-24]. Nevertheless, even though, all of
these studies have shown elevated levels of NKB to be
statistically significant, it perhaps should be noted that
there are significant variations in the amounts of not
only NKB measured from each of the different studies
(some measured in the p/mol range, some n/mol, some
ng/l and some μg/l), but in the fold differences observed
(from 1.3 to 9 fold). Geissbuehler et al. [19] have sug-
gested two reasons for this. The first involves the accu-
racy of NKB determination, which depends crucially on
a reliable sample preparation. Plasma is used in prefer-
ence to serum because the latter contains active pro-
teases, which can affect the antigenicity of peptides.
Currently, NKB levels cannot be measured directly in
plasma and a lengthy and laborious acidified peptide
extraction protocol is employed using Sep-Pak C18 car-
tridges, followed by peptide elution and vacuum centri-
fugation. For instance, Sakamoto et al. [25] calculated a
mean recovery rate of NKB of only 58.4% using this
method. The second reveals that there can be a high
standard deviation in the pre-eclamptic groups, thereby
reflecting a wider range of NKB levels measured in
these women when compared to normotensive controls.
This is not to be unexpected as the onset; severity and
progression of pre-eclampsia can be significantly distinct
between different women [26]. The type of
immunoassay employed could also produce other differ-
ences. Traditionally, in the detection of NKB a commer-
cial radioimmunoassay has been employed, but more
recently this has been superseded by the utilisation of a
commercial enzyme-linked immunosorbant assay
(ELISA) [19,24,27]. Nonetheless, Geissbuehler et al. [19]
found a high correlation between results of the RIA and
ELISA in determining NKB concentrations in plasma
supporting the effective use of both. We have also found
comparable results between the RIA and ELISA when
analysing placental chromatographic fractions. Neverthe-
l e s s ,a l t h o u g h ,t h eR I Ad o e sp r o v i d eah i g h l ys e n s i t i v e
method to measure NKB levels, the ELISA provides a
more simplified protocol and can be completed on a
single day rather than spread over 2 to 3 days, as is the
case with the RIA. There are also issues in designing
new NKB immunoassays. The current immunoassay for-
mat is based on a commercial one site immunoassay,
however, particular difficulties can be encountered when
trying to accommodate two immunoglobulins on such a
short peptide; for instance when developing two site
immunoassay formats. For example, it has been reported
that when testing a two site immunoassay with ‘in
house’ antibodies raised against the two halves of NKB
(DMHDF and FVGLM-NH2) only trace amounts of
NKB in the plasma from pre-eclamptic women and only
minute amounts of NKB in placental extracts could be
detected when compared to the results of the commer-
cial RIA [28]. This briefly lead to a hypothesis that NKB
i nt h ep l a c e n t am a yn o tb ea m i d a t e da n di n s t e a dm a y
have the extended sequence of DMHDFFVGLMGKR
(1.55 kDa) which perhaps only the RIA could detect
[28]. However, it was noted at the time that this was
unusual as antibodies raised against much longer
COOH-terminally amidated peptides can be very speci-
f i cf o rt h eC O O H - a m i d ea n do f t e nd on o tr e c o g n i z e
COOH extended forms of the same peptide. We accord-
ingly tested the commercial antibody to determine
whether it could recognize a non-amidated form of
NKB using the synthetic peptide; glycine COOH-termin-
ally extended NKB (DMHDFFVGLMG). This synthetic
peptide showed no significant cross-reactivity with the
commercial NKB antibody [24,27] indicating that amida-
tion was a crucial part of the natural epitope recognized.
In addition, we found that substance P (1.34 kDa) and a
peptide (KRDMHDFFVGLMG, 1.55 kDa) with the same
molecular mass as the proposed peptide
(DMHDFFVGLMGKR) eluted 2 and 3 fractions ahead
respectively of the NKB immunoreactive peak found in
pre-eclamptic placenta extracts when using the commer-
cial antibody on a Superdex® Peptide HR 10/30 column
[27]. This indicated that the proposed extended NKB
peptide was significantly larger in molecular mass than
could be actually detected in placenta immunologically.
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one site RIA or ELISA assay appears the most effective
method at detecting NKB in plasma and placenta
samples.
In general, the differential diagnostic value of NKB has
been determined predominantly around term, but does
it have any predictive value early in pregnancy? We ori-
ginally found low or undetectable levels of NKB
throughout normotensive pregnancies though a propor-
tion did exhibit higher levels during the first trimester
comparable to levels found at term [6]. A few studies
have consequently analysed NKB plasma levels during
normal pregnancy [25,29,30] using longitudinal studies
covering the period of weeks 8 to 40. D’Anna et al. [29]
showed that there was a slight non-significant increase
of NKB throughout the different stages of normal preg-
nancy. They concluded that their data was in accor-
dance with the original findings [6] reporting the
highest concentrations at term. Interestingly, their
results also contained one to three women in each
group of ten (weeks 11-13, 14-17, 22-26) who had levels
of NKB substantially higher than the mean at 37-40
weeks although none of their women went on to
develop pre-eclampsia. This perhaps indicated that they
had identified pregnant women who were secreting ‘cor-
rective’ levels of NKB into their maternal bloodstreams
[11]. Sakamoto et al. [25] showed similar increasing
levels of NKB, but did find these to be significant,
between weeks 24-35 and 36-40, when compared to
non-pregnant women. They also observed levels of NKB
within 48 hours postpartum that were significantly
lower than those found between 36-40 weeks of preg-
nancy. Taken together, these findings were interpreted
that as placental mass increases there is a corresponding
increase of NKB in the maternal bloodstream confirm-
ing the local production of NKB to be the placenta.
More recently, Li et al. [22] have looked at the differ-
ences in NKB plasma levels in normotensive and pre-
eclamptic pregnancies in a longitudinal study between
weeks 10-14 and 30-34 of gestation. They found mater-
nal plasma levels of NKB to be significantly increased in
early pregnancy before the onset of clinical symptoms.
This difference was unique to the pre-eclamptic group
and was not significant between gestational hypertensive
and normotensive pregnancies [22]. This is the first
direct evidence that NKB could have a predictive value
before the onset of clinical symptoms. In spite of this,
an earlier study measuring NKB levels between weeks
10-20 of pregnancy in women who developed pre-
eclampsia or delivered growth restricted babies found
no difference in NKB plasma levels [30]. Other interest-
ing results have also become apparent with one study
confirming elevated levels of NKB in pre-eclamptic
women that could be split into two cohorts those with
higher and lower concentrations of NKB [19]. The only
clinical difference between the groups was that gravidity
and parity were both higher in the high NKB cohort.
This could perhaps indicate a more adverse reaction fol-
lowing sensitization to a first pregnancy. Differences in
NKB levels between ethnic groups with pre-eclampsia
have also been observed between those of a ‘mixed
ancestry’ presenting with substantially higher levels of
plasma NKB from those of a ‘black ancestry’ [21]. These
variations occurred even though no significant differ-
ences in maternal clinical data were found between the
two ethnic groups. Furthermore, NKB could possibly be
used to differentiate between mild and severe pre-
eclampsia. Immunostaining of human placental samples
with a monoclonal NKB antibody revealed quantifiable
levels of NKB immunoreactive staining of which those
with mild (P > 0.05) or severe pre-eclampsia (P > 0.01)
had significantly higher NKB staining levels than women
in the control group [23].
It would seem apparent that NKB could have a diag-
nostic role to play at term and could also serve a role in
determining differences between those with differing
severities of the disorder. This may serve to allow some
degree of sorting of pregnant women into different cate-
gories that can then be used to improve their clinical
management. Its role as a predictor in earlier pregnancy
before the onset of clinical symptoms is less clear.
Although Li et al. [22] have confirmed predictive levels
as early as weeks 10-14, other studies suggest that
higher levels could be secreted in some patients who
subsequently do not go on to develop pre-eclampsia.
Further longitudinal studies are required to ascertain the
predictive value of NKB and to determine at what gesta-
tional age it may be useful. NKB will have a more signif-
icant predictive value to the obstetrician if it can predict
pre-eclampsia before the onset of symptoms. Regretta-
bly, the current protocols for testing still involve a
tedious extracted plasma assay and there does not seem
to be a more user friendly and robust microtitre plate
assay on the horizon quite yet. The detection of high
levels of NKB remains unique to pregnancy and has not
yet been associated with any other hypertensive disor-
ders. However, high levels of NKB have recently been
associated with other gestational diseases including
intrauterine growth restriction (IUGR) [18] and pre-
term labour [31] all of which can co-present with pre-
eclampsia. NKB may therefore be able to provide an
indication to the level of placental dysfunction.
What is the cause of the elevated levels of NKB
during pre-eclampsia?
Defective trophoblast invasion has been described as a
consistent feature of pre-eclampsia that can lead to pla-
cental ischaemia and the potential release of NKB as a
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placental unit. Proposed physiological triggers include
hypoxia [32] and oxidative stress [33] and these have
been shown to have an effect on the expression of a
range of placental factors. Elevated expression levels of
TAC3a r ef o u n dt ob es i g n i f i c a n t l yh i g h e ri np r e -
eclamptic placenta at term when compared to controls
[22,34]; a result consistent with the theory that TAC3
expression could be up-regulated in response to poor
placental perfusion. However, it is still not known at
what stage in pregnancy these differences first occur. In
spite of this, term placental cytotrophoblasts grown in
hypoxic conditions were found to be associated with
decreases in TAC3 expression, whilst cytotrophoblasts
exposed to conditions of oxidative stress demonstrated
no significant changes in TAC3 expression from con-
trols [34]. These data do not appear to support a role
for hypoxia or oxidative stress as an underlying cause of
the elevated NKB levels in pre-eclampsia. Regardless, it
was noted that the outcome was similar to that found
for activin A in cytotrophoblasts whose gene is likewise
down-regulated by hypoxia, but associated with higher
circulating levels of the protein during pre-eclampsia
[35]. In another respect, it is also of interest to note that
Hoang et al. [36] showed that trophoblast hypoxia
induced several proteins that were also found to be tar-
gets of NKB suppression [37]. This lead Sawicki et al.
[37] to hypothesize that excessive NKB could be thus
inhibiting a normal cellular response to hypoxia.
In the rat, where a longitudinal study of TAC3 (which
has 80% sequence identity with human TAC3) expres-
sion could be undertaken during late pregnancy there
was found to be a significant three fold decrease in
TAC3e x p r e s s i o nf r o md a y1 6t o2 1[ 3 4 ] .I ti sn o t
known whether there is a similar decrease in human
TAC3 expression or whether this represents a species-
specific difference. Moreover, by day 19, the expression
of the placental rat NK3 receptor (TACR3) appeared to
be virtually non-existent indicating the gene was
switched off [34]. In essence, it was concluded that in
normal late pregnancy, at least in the rat, there is a
down regulation of the NKB/NK3 ligand-receptor pair
in the placenta [34]; a similar down regulation has also
been reported in the rat uterus [38,39]. A prime candi-
date possibly responsible for the down regulation of the
NKB/NK3 ligand-receptor pair in late pregnancy is pla-
cental estrogen [34]; where its synthesis occurs expo-
nentially with the highest serum levels reached in late
pregnancy [38]. Furthermore, computer analysis of the
human TAC3 gene promoter has revealed the presence
of estrogen response elements and many potential half
sites [13]. Cintado et al. [40] tentatively suggested that
the NKB/NK3 pair could be involved in or, at least be,
an indicator of estrogen-related pathophysiologies.
Indeed, low circulating levels of estrogen have been
associated with pre-eclampsia [41]. Therefore, in the
case of pre-eclampsia, possible mechanisms of high
NKB expression could include the disruption/failure to
down-regulate the NKB/NK3 system during the third
trimester as observed in the rat, or represent an
unknown stimulus inducing NKB expression [34].
Genomic analysis has also been performed to deter-
mine whether the altered circulating NKB levels are due
to sequence variants in the encoding TAC3a n dTACR3
genes [42]. Mutations were identified in the promoter,
intronic and exonic regions but no association could be
demonstrated between NKB level range and any particu-
lar genotype or haplotype in the pre-eclamptic or con-
trol groups [42]. On the whole the lack of a clear
relationship between any polymorphism and circulating
NKB has suggested that regulation of these genes occurs
at another level other than transcription [42]. Indeed,
we had previously noted that many studies had reported
higher fold levels of circulating NKB peptide than have
been reported in mRNA placental expression levels [34].
Therefore, it is likely that circulating levels of NKB will
be determined by many other factors including the man-
ner of processing, turnover, storage, secretion and
degradation which are not reflective of mRNA levels.
Adding weight to this proposition is the fact that we
found very little, if any, processed NKB in normal term
placenta [24,27]. Instead the predominant NKB-like
immunoreactivity was found in peaks of much larger
molecular mass. A similar observation has also been
reported by Lowry [43] who observed that the placental
concentrations of processed NKB peptides from normal
pregnancies were very low and extracts contained more
partially processed material than fully processed pro-
ducts. This was also evident in the maternal blood
where NKB precursor peptides could also be found [43].
In contrast the chromatographic profiles from term pre-
e c l a m p t i cp l a c e n t ah a das i n g l ep e a kt h a tc o n t a i n e ds i g -
nificant amounts of processed NKB that corresponded
to that of NKB found in the rat brain and to that of syn-
thetic NKB [24,27]. This would indicate that although
changes are seen at the mRNA expression level the
most striking differences are those seen at the level of
post-translational processing. It has been proposed that
these differences occur as a possible result of differential
processing (or lack of during normal pregnancy) at the
NH2-terminal dibasic cleavage site of NKB [24,27]. This
could be the result of increased activity of certain pro-
hormone convertases during pre-eclampsia [27]. Indeed,
there is evidence to support the fact that many peptides
are not fully processed in the normal placenta but
undergo processing to active peptides during pre-
eclampsia [44,45]. This could represent part of the
mechanism that leads to the increased circulating levels
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explaining the differences of NKB concentrations in
maternal blood [24].
What is the physiological significance of NKB in
the placenta?
The physiological roles of NKB in the placenta are only
just starting to unravel themselves, but one thing is
clear the expression levels of TAC3 in the placenta are
considerably higher than in any other organ or tissue in
the human body so far analysed [11,34]. Traditionally,
classified as a neurotransmitter placental NKB expres-
sion levels are found to be 2.6 fold higher than that in
the brain [24] and since, the placenta does not have any
neuronal connections; its main action here is proposed
to be endocrine rather than neuronal. Several studies
have substantiated that the main site of this expression
is the outer syncytiotrophoblasts [6,22,23,31], a layer of
cells, which are in an ideal position to secrete NKB into
the bloodstream. From here, NKB has been demon-
strated not only to enter the maternal blood circulation
but also to enter the fetal circulation [6,20,25]. Further-
more, significantly higher levels of NKB have been
reported in the umbilical cord of pre-eclamptic women
when compared to normotensive pregnant women [20].
It is most likely that the secretion of NKB from the pla-
centa is continuous being by the constitutive pathway
opposed to being stored in secretory granules (as in
neuronal tissue). This may account for the fact that
even though placental TAC3 mRNA levels are higher
than those found in the brain typically NKB peptide
levels found in pre-eclamptic placenta are three times
lower than those detected in rat brain [24]. In addition,
for a tachykinin peptide, such as NKB, to possess ago-
nist activity it is important for it to have undergone
COOH-terminal amidation [46]. This can only happen if
the precursor protein fromw h i c hN K Ba r i s e si sf u l l y
processed. There is evidence to support the fact that
very little processing of NKB actually occurs in the nor-
mal placenta [24,27,43]. Indeed, it appears that most
NKB is fully processed only in the pre-eclamptic pla-
centa [24,27] and therefore the condition somehow
represents a switch to the production of active NKB.
This raises questions regarding the physiological signifi-
cance of NKB during normal pregnancy as it is unclear
how much active peptide is being produced to be
secreted. However, it is clear that even in early normal
pregnancy processed NKB can start to enter the mater-
nal bloodstream at varying concentrations in different
women [6,22,29].
The biological effect of NKB, for example, constriction
or dilation of blood vessels depends on the relative tis-
sue distribution of, and binding to, the three tachykinin
receptor subtypes given here in order of affinity for
NKB, NK3>NK2>NK1 [9]. More recently, we identified
the molecular mechanism that leads to the formation of
a truncated form of the NK1 receptor, which we have
found to be predominantly expressed in peripheral tis-
sue including the placenta where it is proposed to have
slightly different pharmacological properties from the
full length NK1 receptor [10]. A fourth NK4 receptor
had also been cloned from a human placental cDNA
library [47]. After subsequent investigation we unfortu-
nately found this receptor to be the guinea pig NK3
receptor [48]. Our first indication of a physiological role
for NKB in the utero-placental unit came following our
observation of a 37% gain in weight of the uteri of rats
infused with chronic doses of NKB providing indirect
evidence for an increase in blood supply to the uterus
[6]. Thus, we proposed that activation by NKB might
play a role in local nitric oxide (NO) release, where NO
production by the vascular endothelium of the utero-
placental circulation has been well documented in
humans [13]. D’Anna et al. [18] has shown a significant
correlation between pregnancies complicated with pre-
eclampsia and IUGR, increased NKB plasma levels and
increased NO metabolite levels. In addition, our original
hypothesis suggested that following reduced placental
perfusion, NKB would be secreted, to compensate, by
increasing blood flow to the fetal-placental unit. This
scenario has been supported by observations using per-
fused human placental cotyledons [49] and placental
stem villous arteries [50]. These studies used precon-
struction with U-46619 to show that NKB acted as a
dilator in the placental vasculature [49,50], where this
effect was found to be initiated solely though the NK1
receptor. The NK1 receptor is associated with vasodila-
tory responses [6], and evidence has shown that the
vasoconstrictive NK3 receptor is either absent or
expressed at extremely low levels in the human placenta
at term when compared to the NK1 and NK2 receptors
[34,49]. This would advocate a mechanism in the
human placenta, whereby high NKB levels induce pla-
cental vasodilatation via the NK1 receptor to maintain
low placental resistance. However, no evidence for the
involvement of either NO or prostacyclin in this
response was found by Brownbill et al. [49]. Laliberte et
al. [50] found that removal of the endothelium from the
villous arteries did not alter the vasodilatory response
concluding that NKB caused an endothelium-indepen-
dent relaxation of the placental arterial vessels. None-
theless, pre-eclampsia is typically associated with
maternal vasoconstrictive responses and we proposed
that activation of NK3 receptors on the venous side of
the maternal circulation could be responsible for the
hypertension that develops during pre-eclampsia [6,11].
The observation of NK3 receptors in the circulatory sys-
tem had remained an enigma up to this time [11]. In
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doses of NKB caused a significant, albeit transient, rise
in mean arterial blood pressure [6]. Yang et al. [51] have
gone further to analysis this response following the
chronic infusion of NKB into female rats finding the
cardiovascular responses to be both dose-dependent and
bimodal. Low dose NKB was found to reduce resting
systemic blood pressure, and reduce vascular reactivity
to phenylephrine in vivo and in vitro. By contrast, high
dose NKB increased resting blood pressure, increased
the pressor response to angiotensin II in vivo and
increased maximum phenylephrine induced vasocon-
striction in vitro. The effects of low dose NKB were
shown to be through the direct modulation of vascular
tone, while chronic high dose NKB induced increases in
blood pressure through both central and peripheral
pathways [51]. This would appear to support a mechan-
ism whereby in normal pregnancy NKB may contribute
to the modest fall in systemic blood pressure and
reduced vascular tone, however high levels may contri-
bute to raising blood pressure and increasing the pressor
sensitivity to angiotensin II as seen in pre-eclampsia.
However, this rationale has not received universal accep-
tance and Wareing et al. [52] concluded that NKB was
not a circulating factor associated with increase vascular
resistance as it did not in their isolated vessel system
alter vasoactive responsiveness. On the other hand,
Yang et al. [51] stress that treatment of intact animals
with high dose NKB more closely mimics the situation
of pre-eclampsia than acute incubation of blood vessels
in vitro.
Beyond the hypertension, the discovery of secreted
NKB during pre-eclampsia has led other researchers to
investigate some of the other associated symptoms of
pre-eclampsia. In severe cases of pre-eclampsia, we pre-
dicted that concentrations of NKB may be high enough
to stimulate peripheral NK1 receptors on platelets.
Since, a major complication of pre-eclampsia is platelet
pathology; Graham et al. [14] examined a potential per-
ipheral role for tachykinins in the regulation of platelet
function. They reported the expression of NK1 and NK3
receptors on human platelets, and found that the level
of activation of platelets by the tachykinin substance P
is reduced in NK1 receptor-deficient mouse platelets.
Subsequently, it has been demonstrated that inhibition
of the NK1 receptor results in substantially reduced
thrombus formation in vitro under arterial flow condi-
tions, increased bleeding times in mice, and a decrease
in experimentally induced thromboembolism [53]. This
has lead to the proposal that tachykinins may play a key
role in the positive feedback regulation of platelet aggre-
gation and thrombus formation and may offer an alter-
native therapeutic target to those currently available.
The significance of the NK3 receptor on platelets is
currently unknown. In another facet, multi-organ
oedema is one of the signs of pre-eclampsia, and acute
pulmonary oedema is a major cause of death in those
affected by pre-eclampsia [54]. Substance P is a well-
established peripheral pro-inflammatory peptide and is a
potent mediator of increased microvascular permeability,
leading to plasma extravasation and tissue oedema for-
mation. Until, fairly recently, a possible role for NKB in
peripheral pathologies had not received much attention
as it had never before been found in the periphery [6].
Data now suggests that intravenous administration of
NKB into wild-type mice can produce significant plasma
extravasation in skin, uterus, liver and particularly in the
lung [16]. Unexpectedly, the results also indicated a
novel NK receptor independent pathway specific to
NKB that operates in the mouse lung. Grant et al. [16]
concluded that their data was in keeping with a role for
NKB in mediating plasma extravasation in diseases such
as pre-eclampsia. Nonetheless, the most dangerous com-
plication of pre-eclampsia is the generalized tonic/clonic
convulsions of eclampsia that affects the whole brain.
Wasseff [17] has hypothesized that it is the effect of ele-
vated NKB that may trigger the convulsions both,
directly by enhancing glutamatergic pathways, and indir-
ectly through endothelial activation and endothelin
release. Wasseff [17] concludes that these findings
strongly suggest that NKB plays a role in altering neuro-
nal excitability in eclampsia. Nonetheless, this is a com-
plex area with several factors also implicated such as
proinflammatory cytokines with parallels also drawn
between the seizures of eclampsia and those of epilepsy
[17].
There is also evidence to support an autocrine/para-
crine role for NKB in the placenta. Female rats treated
with the NK3 receptor antagonist SR142801 before mat-
ing exhibited a tendency towards decreased fertility with
a significant reduction in their litter sizes [55]. In addi-
tion, the highest levels of uterine NK3 receptor expres-
sion in the pregnant rat (peaking at day 3) are detected
before and at the time of implantation [38]. NKB could
therefore play a key role in modulating implantation in
early pregnancy. Indeed, in humans, elevated levels have
also been associated with IUGR that like pre-eclampsia
occurs with impaired placental implantation and the
early failure of trophoblast invasion may represent a
time of sustained NKB synthesis [34]. Evidence from
direct treatment of term villous cytotrophoblasts with
NKB also finds the suppression of several proteins
important in the cellular response to oxidative stress
and hypoxia [37], which could compound the placental
reaction to NKB. More recently, it has become evident
that a key component in regulating trophoblast cell sur-
vival and function is an imbalance between circulatory
pro-angiogenic and anti-angiogenic factors [1]. The
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factors. One notable factor, soluble flt-1 (sFLT-1) acts as
an anti-angiogenic factor by interacting with, and
thereby neutralising the effects of vascular endothelial
growth factor (VEGF) and placental growth factor
(PIGF) [56] therefore reducing the effects at the VEGF
receptor-1 (VEGFR-1) and VEGFR-2 receptors, respec-
tively. Increased blood levels of sFLT-1 are shown to
correlate with the severity of pre-eclampsia, whereas,
opposing, the quantities of VEGF and PIGF are
decreased in women with pre-eclampsia compared to
controls. In 2006, Pal et al. [57] reported that NKB was
an anti-angiogenic factor that inhibited endothelial cell
vascular network assembly and opposed angiogenesis.
The functional consequences of this cause a direct
down-regulation of VEGFR-1 and VEGFR-2 expression,
with a corresponding down regulation of VEGF,
decreased cell motility and increased calreticulin synth-
esis [57]. Therefore, NKB joins a growing list of compo-
nents that may be responsible for creating an anti-
angiogenic environment that leads up to the develop-
ment of pre-eclampsia. As an aside, when attempting to
isolate NKB from placenta Lovell et al. [58] have
detected a number of co-purifying substances presumed
t ob ei nt h em o l e c u l a rr a n g e0 . 9-1 . 3k D a( c . f .N K B
1.21 kDa). They speculate that these could be autolytic
by-products of NKB and other peptides that contain an
attached phosphocholine group, which could play a
paracrine role when secreted and exposed at the placen-
tal interface in order to reduce anti-placental directed
antibodies [58]. Their significance still needs to be veri-
fied with Lowry [43] reporting that their characterisation
will be difficult because of several reasons including
their extremely low concentrations, the lack of a purified
preparation that gives a clean mass ion and the availabil-
ity of good quality placenta.
Conclusion
The precise etiopathogenesis of pre-eclampsia remains
the subject of much debate and intensive research. The
last ten years has heralded many advances and revealed
potential new markers, yet no defining predictive test is
yet available to identify women who will subsequently
develop pre-eclampsia. This is likely to reflect the fact
that pre-eclampsia is multifactorial with an onset, sever-
ity and progression that can be significantly distinct in
different women. This raises questions to the presence
of factors such as NKB to whether they are causative or
merely associated with pre-eclampsia. Yet, there is evi-
dence to support a role for NKB right from the time of
implantation to the high levels found circulating in the
blood of pre-eclamptic women at term. It is apparent
t h eh i g hl e v e l so fc i r c u l a t i n gN K Ba r ead i a g n o s t i cf e a -
ture of pre-eclampsia at term, but its role as an
indicator before the onset of symptoms is less clear.
Longitudinal studies are still required along with the
development of a user friendly and robust test that can
be performed directly using plasma. In terms of under-
standing the regulation of genes involved in pre-eclamp-
sia, the results with TAC3 indicate not only to take into
account the possibility of up-regulation, but the poten-
tial failure/disruption to down-regulate. The role of hor-
mones such as estrogen in these responses will be
interesting to investigate for their effect on gene expres-
sion. However, the main mechanism of control appears
at the level of post-translational modification and may
indicate that a general increased activity of certain pro-
cessing enzymes occurs during pre-eclampsia. This
could go some way to explaining the increased plethora
of vasoactive peptides that are secreted during pre-
eclampsia and is certainly worthy of further research to
determine whether there are common processing path-
ways involved in the elevation of these vasoactive pep-
tides. NKB in the placenta is found to have both
paracrine and endocrine roles. In a paracrine role it may
modulate implantation, suppress several proteins
involved in the cellular response to hypoxia and oxida-
tive stress and act as an anti-angiogenic factor. Locally,
it maintains low placental resistance, while its dose
dependent and bimodal effects support a mechanism
whereby in normal pregnancy it contributes to the mod-
est fall in blood pressure and reduced vascular tone,
whilst at high doses it contributes to raising blood pres-
sure and increasing pressor sensitivity as seen in pre-
eclampsia. Animal models also show that in the periph-
ery NKB can have significant effects on platelet clotting
and lung oedema. The repetition of animal studies with
potent and selective combinations of NK receptor
antagonists is needed to show their potential effective-
ness in the treatment of pre-eclampsia. NK3 antagonists
might alleviate the effects of high NKB in the plasma of
mothers suffering from pre-eclampsia, whilst NK1
antagonists could control the effects of thrombocytope-
nia and generalized inflammation. Moreover, recent
research has shown a diversity of mechanisms such as
mRNA splicing, precursor processing and post-transla-
tion modification that can lead to a complex and conti-
nually expanding repertoire of tachykinin peptides. The
proteomic analysis of the tachykinins has been hindered
by the lack of specific methodologies to capture, purify
and characterize them and it will be important in the
future to develop these methodologies [59]. We look
forward to the next ten years of research in the field of
tachykinins and pregnancy!
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